Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study.
COVID-19 vaccine
Japan
SARS-CoV-2 antibody titer
healthcare workers
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
pubmed:
22
2
2022
medline:
20
4
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
Objective We evaluated the change in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers from three to six months after the administration of the BNT162b2 vaccine among healthcare workers. Methods A total of 337 healthcare workers who received 2 doses of the BNT162b2 vaccine were included in this study. Factors associated with SARS-CoV-2 antibody titers at three and six months and the change in SARS-CoV-2 antibody titers between three and six months after vaccine administration were analyzed using a logistic regression analysis. Results The SARS-CoV-2 antibody titer at 3 months was 4,812.1±3,762.9 AU/mL in all subjects and was lower in older workers than in younger ones. The SARS-CoV-2 antibody titer at 6 months was 1,368.9±1,412.3 AU/mL in all subjects. The SARS-CoV-2 antibody titers that were found to be high at three months were also high at six months. The change in SARS-CoV-2 antibody titers from 3 to 6 months was -68.9%±16.1%. The higher SARS-CoV-2 antibody titers at three months showed a more marked decrease from three to six months than lower titers. Conclusion This study demonstrates that SARS-CoV-2 antibody titers at three months decreased with age and were associated with the antibody titers at six months and the change in titer from three to six months. Older individuals in particular need to be aware of the declining SARS-CoV-2 antibody titers at six months after the BNT162b2 vaccine. The results of this study may provide insight into COVID-19 vaccine booster strategies.
Identifiants
pubmed: 35185050
doi: 10.2169/internalmedicine.8902-21
pmc: PMC9107982
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1139-1143Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5
pubmed: 34375755
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Sci Rep. 2021 Jul 2;11(1):13733
pubmed: 34215803
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Geriatr Gerontol Int. 2021 Jan;21(1):60-65
pubmed: 33264816
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4
pubmed: 34508885
Vaccines (Basel). 2021 Sep 18;9(9):
pubmed: 34579279
Clin Chem Lab Med. 2021 Dec 16;60(3):456-463
pubmed: 34911170
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307